<p>With coronavirus vaccines now available, what are the timeline and prospects for "herd immunity" and return to a new normal? Marc Lipsitch, DPhil, of Harvard T.H. Chan School of Public Health returns to JAMA's Q&A series with Paul D. Biddinger, MD, director of Massachusetts General Hospital's Center for Disaster Medicine, to discuss. Recorded December 17, 2020.</p> <p>Related Article(s):</p> <ul> <li><a href= "https://edhub.ama-assn.org/jn-learning/audio-player/10.1001/jama.2020.25412"> COVID-19 Vaccines and Herd Immunity</a></li> <li><a href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.25053"> The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials</a></li> <li><a href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.25127"> Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines</a></li> <li><a href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.20892"> Herd Immunity and Implications for SARS-CoV-2 Control</a></li> <li><a href= "https://edhub.ama-assn.org/jn-learning/audio-player/10.1001/jama.2020.22332"> Herd Immunity as a Coronavirus Pandemic Strategy</a></li> </ul>

Digital Health—The Need to Assess Benefits, Risks, and Value

Go beyond the latest discoveries with nuanced, in-depth conversations in Healthy Dialogue, a podcast from the JAMA Network. Host and JAMA Senior Editor, Derek C. Angus, MD, MPH, sits down with the world's leading experts to explore the most pressing issues in health and health care.